Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Gastroenterology

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.gastro.2015.10.013PMID 26497081PMCID PMC4727992
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2

  2015cited by this paper
• Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

  2015cited by this paper
• LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1

  2015cited by this paper
• Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.

  2015cited by this paper
• Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon‐ineligible/intolerant individuals

  2014cited by this paper
• Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.

  2014cited by this paper
• Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

  2014cited by this paper
• Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.

  2014cited by this paper
• Overall safety profile of boceprevir plus peginterferon alfa‐2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials

  2014cited by this paper
• Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.

  2013cited by this paper
• Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence

  2013cited by this paper
• Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta‐analysis

  2013cited by this paper
• Determination of reliability criteria for liver stiffness evaluation by transient elastography

  2013cited by this paper
• Global control of hepatitis C: where challenge meets opportunity

  2013cited by this paper
• Gaps in the achievement of effectiveness of HCV treatment in national VA practice.

  2012cited by this paper
• Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

  2012cited by this paper
• The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors

  2012cited by this paper
• Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV.

  2012cited by this paper
• Racial differences in hepatitis C treatment eligibility

  2011cited by this paper
• A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

  2011cited by this paper
• A Review of Hot Deck Imputation for Survey Non‐response

  2010cited by this paper
• Outcome of sustained virological responders with histologically advanced chronic hepatitis C

  2010cited by this paper
• Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support

  2009cited by this paper
• Limited Uptake of Hepatitis C Treatment Among Injection Drug Users

  2008cited by this paper
• Using Inverse Probability-Weighted Estimators in Comparative Effectiveness Analyses With Observational Databases

  2007cited by this paper
• Statistical Analysis with Missing Data

  1988cited by this paper
• A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity

  1980cited by this paper

• Late Hepatocellular Carcinoma Occurrence in Patients Achieving Sustained Virological Response After Direct-Acting Antiviral Therapy: A Matter of Follow-Up or Something Else?

  2024cites this paper
• Global treatment rate and barriers to direct‐acting antiviral therapy: A systematic review and meta‐analysis of 146 studies and 1 760 352 hepatitis C virus patients

  2023cites this paper
• Therapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus.

  2023cites this paper
• A Synopsis of Hepatitis C Virus Treatments and Future Perspectives

  2023cites this paper
• Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients

  2022cites this paper
• The Effect of Sofosbuvir Administration on Albino Rats’ Buccal Mucosa (Histological and immunochemical study)

  2022cites this paper
• Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.

  2022cites this paper
• Special Collection: A pioneer in antiviral drug discovery and development: Commemorating John Martin Review

  2022cites this paper
• Factors Associated with the Refusal of Direct-Acting Antiviral Agents for the Treatment of Hepatitis C in Taiwan

  2022cites this paper
• Breakthroughs in hepatitis C research: from discovery to cure

  2022cites this paper
• The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors

  2021cites this paper
• Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma.

  2021cites this paper
• High Effectiveness of Broad Access Direct‐Acting Antiviral Therapy for Hepatitis C in an Australian Real‐World Cohort: The REACH‐C Study

  2021cites this paper
• Neurologische Komplikationen der Hepatitis-C-Infektion

  2020cites this paper
• Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan

  2020cites this paper
• Comparing Daclatasvir plus Sofosbuvir, with or without Ribavirin, for Hepatitis C virus genotype 3 Management.

  2020cites this paper
• Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure

  2020cites this paper
• Development and Validation of a New Method for the Determination of Anti-hepatitis C Agent Simeprevir in Human Plasma using HPLC with Fluorescence Detection

  2020cites this paper
• Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam

  2020cites this paper
• Drug-Induced Liver Injury in the Setting of Chronic Liver Disease.

  2020cites this paper
• While direct‐acting antivirals are effective, are there any unique safety considerations?

  2020cites this paper
• Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data.

  2020cites this paper
• Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France

  2020cites this paper
• Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.

  2020cites this paper
• Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment.

  2020cites this paper
• Effectiveness of direct‐acting agents for hepatitis C and liver stiffness changing after sustained virological response

  2019cites this paper
• Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort

  2019cites this paper
• Exploring Links between Melatonin, Inflammation and Depression

  2019cites this paper
• Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.

  2019cites this paper
• The Hepatitis C Virus Care Continuum: Linkage to Hepatitis C Virus Care and Treatment Among Patients at an Urban Health Network, Philadelphia, PA

  2019cites this paper
• Effectiveness of 8 Weeks of Ledipasvir/Sofosbuvir for Hepatitis C in HCV–HIV-Coinfected Patients

  2019cites this paper
• Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial.

  2019cites this paper
• Real-World Evidence and Hepatitis C

  2019cites this paper
• Direct‐acting antiviral agents in the treatment of chronic hepatitis C—Real‐life experience from clinical practices in Pakistan

  2019cites this paper
• Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis

  2019cites this paper
• Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS‐FANTASIO study)

  2019cites this paper
• Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy

  2019cites this paper
• Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil.

  2019cites this paper
• Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis

  2019cites this paper
• Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy

  2019cites this paper
• Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis

  2019cites this paper
• HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics

  2019cites this paper
• Treatment Outcomes of Hepatitis C-Infected Patients in Specialty Clinic vs. Primary Care Physician Clinic: A Comparative Analysis

  2019cites this paper
• Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

  2019cites this paper
• Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank

  2019cites this paper
• Interferon-free therapy in hepatitis C virus (HCV) monoinfected and HCV/HIV coinfected patients: effect on cognitive function, fatigue, and mental health

  2018cites this paper
• Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment‐Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis

  2018cites this paper
• Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting

  2018cites this paper
• Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world

  2018cites this paper
• Advances in Treatment of Hepatitis C Sanaa

  2018cites this paper
• Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort

  2018cites this paper
• The adverse effects of interferon‐free regimens in 149 816 chronic hepatitis C treated Egyptian patients

  2018cites this paper
• Influence of baseline MELD score in the efficacy of treatment of hepatitis C with simeprevir and sofosbuvir.

  2018cites this paper
• Effectiveness of direct-acting antiviral therapy in patients with a HCV/HIV coinfection. A multicenter cohort study.

  2018cites this paper
• Direct-actng antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital

  2018cites this paper
• Real-world treatment of hepatitis C with second-generation direct-acting antivirals: initial results from a multicentre Canadian retrospective cohort of diverse patients.

  2018cites this paper
• Baseline NS5A resistance associated substitutions may impair DAA response in real‐world hepatitis C patients

  2018cites this paper
• Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study

  2018cites this paper
• Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study

  2018cites this paper
• Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses

  2018cites this paper
• Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy

  2018cites this paper
• All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response

  2018cites this paper
• Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population

  2018cites this paper
• Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries

  2018cites this paper
• Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon‐free treatment era

  2018cites this paper
• Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals

  2018cites this paper
• Hand-foot syndrome due to hepatitis C therapy.

  2018cites this paper
• Expert opinion on the management of hepatitis C infection in Kuwait

  2018influential citation
• The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong

  2018cites this paper
• Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?

  2018cites this paper
• Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.

  2018cites this paper
• Expanding Capacity to Treat Hepatitis C: Overcoming Barriers and New Innovations

  2018cites this paper
• Efficacy and Safety of Simeprevir-Sofosbuvir Combined Therapy for Treatment of Chronic Hepatitis C Virus Infection

  2018cites this paper
• Hepatitis C Treatment in the Era of Direct-Acting Antiviral Agents: Challenges in Developing Countries

  2018cites this paper
• Influencia de la puntuación MELD basal en la eficacia del tratamiento de la hepatitis C con sofosbuvir y simeprevir

  2018cites this paper
• Epidemiological studies on viral infections and co-infections: Human immunodeficiency virus, hepatitis C virus and human papillomavirus

  2018influential citation
• Hepatitis C

  2018cites this paper
• HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs

  2017cites this paper
• Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients.

  2017cites this paper
• Direct‐acting antivirals in hepatitis C virus (HCV)‐infected and HCV/HIV‐coinfected patients: real‐life safety and efficacy

  2017cites this paper
• Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older

  2017cites this paper
• Hepatitis C Virus-Associated Cancers.

  2017cites this paper
• Simeprevir plus sofosbuvir for eight or 12 weeks in treatment‐naïve and treatment‐experienced hepatitis C virus genotype 4 patients with or without cirrhosis

  2017cites this paper
• Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.

  2017cites this paper
• Hepatitis C Virus Infection and Rheumatic Diseases: The Impact of Direct-Acting Antiviral Agents.

  2017cites this paper
• Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study

  2017cites this paper
• Comparative Study between Triple Therapy (Peginterferon /Ribavirin/Sofosbuvir) and Dual Therapy (Simeprevir /Sofosbuvir) in Treatment of Chronic HCV Patients

  2017cites this paper
• Advances in Treatment of Hepatitis C Advances in Treatment of Hepatitis C Advances in Treatment of Hepatitis C

  2017cites this paper
• Advances in Treatment of Hepatitis C

  2017cites this paper
• Hepatitis C: efficacy and safety in real life

  2017cites this paper
• The Challenge of Treating Children With Hepatitis C Virus Infection

  2017cites this paper
• Current Treatment of Chronic Hepatitis C

  2017cites this paper
• Clinical studies on hepatitis B, C, and E virus infection

  2017cites this paper
• Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil.

  2017cites this paper
• The value of real world data in healthcare decision-making : practical applications using observational data from the National Hepatitis C Treatment Registry

  2017cites this paper
• Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD.

  2017cites this paper
• EASL Recommendations on Treatment of Hepatitis C 2016.

  2017cites this paper
• Efectividad de la terapia combinada con Simeprevir y Sofosbuvir en pacientes con hepatitis crónica por VHC

  2017cites this paper
• Experiencia en práctica clínica real de los nuevos Antivirales de Acción Directa en hepatitis crónica C

  2017cites this paper
• Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil

  2017influential citation